Latest | F'cast | |
---|---|---|
Div Yield | 2.9% | |
Div Cover | 0.0 | |
Op Mrgn | 3.1% | |
ROCE | 5.6% |
Latest | F'cast | |
---|---|---|
P/E | 730.9 | |
PEG | n/a | |
Pr/Revenue | 4.3 | |
Pr/Book | 6.9 |
Latest | F'cast | |
---|---|---|
Revenue | 1.4% | |
PBT | -88.5% | |
EPS | -97.6% | |
DPS | 5.7% |
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-19 | 46,840.00 | 11,464.00 | 384.00¢ | 23.7 | 0.4 | +64% | 226.00¢ | 2.5% |
31-Dec-20 | 47,994.00 | 8,791.00 | 179.00¢ | 45.7 | n/a | -53% | 248.00¢ | 3.0% |
31-Dec-21 | 48,704.00 | 13,879.00 | 488.00¢ | 15.7 | 0.1 | +173% | 264.00¢ | 3.4% |
31-Dec-22 | 59,283.00 | 16,444.00 | 573.00¢ | 19.4 | 1.1 | +17% | 280.00¢ | 2.5% |
31-Dec-23 | 60,115.00 | 1,889.00 | 14.00¢ | 778.7 | n/a | -98% | 296.00¢ | 2.7% |
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-24 | 64,104.68 | 24,114.15 | 775.59¢ | 13.2 | 0.0 | +5,440% | 301.75¢ | 0.0% |
31-Dec-25 | 68,269.60 | 29,178.96 | 971.47¢ | 10.5 | 0.4 | +25% | 315.17¢ | 0.0% |
31-Dec-26 | 72,202.23 | 31,696.06 | 1,068.52¢ | 9.6 | 1.0 | +10% | 329.70¢ | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Merck tops Q3 earnings forecasts despite slower ... | 31-Oct-2024 | ShareCast |
Merck to buy drug targeting B-cell diseases for ... | 09-Aug-2024 | ShareCast |
Merck to buy EyeBio for up to $3bn | 29-May-2024 | ShareCast |
Currency | US Dollars |
Share Price | $ 102.32 |
Change Today | $ -2.51 |
% Change | -2.39 % |
52 Week High | $132.96 |
52 Week Low | $98.60 |
Volume | 17,409,896 |
Shares Issued | 2,531.63m |
Market Cap | $259,037m |
RiskGrade | 92 |
Strong Buy | 11 |
Buy | 11 |
Neutral | 3 |
Sell | 0 |
Strong Sell | 0 |
Total | 25 |
Time | Volume / Share Price |
16:00 | 1,954,517 @ $102.32 |
15:59 | 117 @ $102.31 |
15:59 | 191 @ $102.31 |
15:59 | 326 @ $102.31 |
15:59 | 127 @ $102.32 |
You are here: research